Interventions for Tuberculosis Control and Elimination 2002

443. Nunn P, Kibuga D, Gathua S, Brindle R, Imalingat A, Wasunna K, Lucas S,
Gilks C, Omwega M, Were J, McAdam K. Cutaneous hypersensitivity reactions
due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.
1991; 337: 627-30.
Lancet
444. Ipuge YAI, Rieder HL, Enarson DA. Adverse cutaneous reactions to thiacetazone
for tuberculosis treatment in Tanzania. Lancet 1995; 346: 657-60.
445. Kelly P, Buve A, Foster SD, McKenna M, Donnelly M, Sipatunyana G.
Cutaneous reactions to thiacetazone in Zambia - implications for tuberculosis
treatment strategies. Trans R Soc Trop Med Hyg 1994; 88: 113-5.
446. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal
necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency
virus. J Am Acad Dermatol 1992; 26: 567-74.
447. Dukes CS, Sugarman J, Cegielski JP, Lallinger GJ, Mwakyusa DH. Severe cutaneous
hypersensitivity reactions during treatment of tuberculosis in patients with
HIV infection in Tanzania. Trop Geogr Med 1992; 44: 308-11.
448. Roujeau JC.
111-2.
Toxidermies au cours de l’infection à VIH. Presse Méd 1994; 23:
449. Nunn P, Porter J, Winstanley P. Thiacetazone - avoid like poison or use with
care? Trans R Soc Trop Med Hyg 1993; 87: 578-82.
450. van Gorkom J, Kibuga DK. Cost-effectiveness and total costs of three alternative
strategies for the prevention and management of severe skin reactions attributable
to thiacetazone in the treatment of human immunodeficiency virus positive
patients with tuberculosis in Kenya. Tubercle Lung Dis 1996; 77: 30-6.
451. Sbarbaro J, Blomberg B, Chaulet P. Fixed-dose combination formulations for tuberculosis
treatment. (Editorial). Int J Tuberc Lung Dis 1999; 3(suppl): S286-S288.
452. International Union Against Tuberculosis and Lung Disease. Assuring bioavailability
of fixed-dose combinations of anti-tuberculosis medications. A joint statement
of the International Union Against Tuberculosis and Lung Disease and the
World Health Organization. As approved by the Executive Committee and
Council of the IUATLD, Bangkok, November 1998.
1999; 3(suppl): S282-S283.
Int J Tuberc Lung Dis
453. Anonymous. Quality assurance: protocol for assessing the rifampicin bioavailability
of combined formulations in healthy volunteers.
1999; 3(suppl): S284-S285.
Int J Tuberc Lung Dis
454. Chaulet P. Implementation of fixed-dose combinations in tuberculosis control:
outline of responsibilities. Int J Tuberc Lung Dis 1999; 3(suppl): S353-S357.
455. Blomberg B, Kitler ME, Milstien J, Dellepiane N, Fanning A, Norval PY,
Spinaci S. Availability of quality fixed-dose combinations for the treatment of
tuberculosis: what can we learn from studying the World Health Organization’s
vaccine model? Int J Tuberc Lung Dis 1999; 3(suppl): S371-S380.
198